Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02020707
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:20.977366+00:00
Published At
2024-07-26T00:00:00+00:00
Record Updated At
2024-07-26
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Cervical Adenocarcinoma", "Cervical Adenosarcoma", "Cervical Adenosquamous Carcinoma", "Cervical Carcinosarcoma", "Cervical Squamous Cell Carcinoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Carcinosarcoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Squamous Cell Carcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Malignant Female Reproductive System Neoplasm", "Malignant Ovarian Clear Cell Tumor", "Malignant Ovarian Endometrioid Tumor", "Malignant Ovarian Epithelial Tumor", "Malignant Ovarian Mucinous Tumor", "Malignant Peritoneal Neoplasm", "Malignant Solid Neoplasm", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal Clear Cell Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Unresectable Melanoma", "Uterine Corpus Carcinosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-07-26"
protocolSection.identificationModule.nctId
"NCT02020707"
protocolSection.identificationModule.officialTitle
"Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Cervical Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Cervical Adenosarcoma (protocolSection.conditionsModule.conditions)
  • Cervical Adenosquamous Carcinoma (protocolSection.conditionsModule.conditions)
  • Cervical Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Cervical Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Clinical Stage IV Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Endometrial Adenosquamous Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Mixed Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Malignant Female Reproductive System Neoplasm (protocolSection.conditionsModule.conditions)
  • Malignant Ovarian Clear Cell Tumor (protocolSection.conditionsModule.conditions)
  • Malignant Ovarian Endometrioid Tumor (protocolSection.conditionsModule.conditions)
  • Malignant Ovarian Epithelial Tumor (protocolSection.conditionsModule.conditions)
  • Malignant Ovarian Mucinous Tumor (protocolSection.conditionsModule.conditions)
  • Malignant Peritoneal Neoplasm (protocolSection.conditionsModule.conditions)
  • Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Ovarian Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian High Grade Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Resistant Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Resistant Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Resistant Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Sensitive Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Unresectable Melanoma (protocolSection.conditionsModule.conditions)
  • Uterine Corpus Carcinosarcoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.